Market News

Interspinous Process Decompression Devices Market – Drivers

Since recent past, minimally invasive surgical procedures have gained traction resulting in development of various interspinous process decompression device. The global interspinous process decompression device market is expected to be driven by the new product launches by the market players. For instance, in 2015, Vertiflex, Inc., innovator in minimally invasive intervention for spinal stenosis, received Premarket Approval Application (PMA) order from the U.S. Food and Drug Administration (FDA) for its product, Superion, indicated for moderate lumbar spinal stenosis. The Superion is least invasive motion preserving device in interspinous spacers’ category. In 2015, the implant was successfully implanted in 2,000 patients around the world as a part of study and is expected to be available in the US market during the forecast period.

Moreover, in 2014, Exatech launched Octane Elevate, a new lumbar spacer to restore disc height and addressing anatomical conditions. In 2012, Paradigm Spine’s Coflex (previously called Interspinous U) Interlaminar Technology implant was approved by the FDA through the premarket approval process for one- or two-level lumbar stenosis from L1 to L5 producing at least moderate impairment in skeletally mature patients. Moreover, according to Permera Blue cross, the US-based medical insurance company, NL-Prow (by Non-Linear Technologies), Aperius (by Medtronic plc.), and Falena (by Mikai) devices are in trials in Europe.

Moreover, reimbursement policies are expected to fuel growth of the interspinous process decompression device market. For instance, in 2016, the International Society for the Advancement of Spine Surgery (ISASS) published recommendations and coverage criteria for decompression with interlaminar stabilization. However, lack of national coverage determination handover the policy discretion to local Medicare carriers.